



## CURRICULUM VITAE MEDICAL

Date : 13 Juillet 2023

### A. DONNEES IDENTITE:

Nom : **SERONT** ..... Lieu/date naiss.: Haine Saint Paul 24/07/1979  
Prénoms: **Emmanuel** ..... Nationalité: Belge.....  
Tél.: +32 2 764 5106 / 5109 .....  
adresse mail : emmanuel.seront@saintluc.uclouvain.be.....

### B. FONCTION CLINIQUE ACTUELLE:

Oncologue Médical, Groupe Jolimont, Haine-Saint-Paul (Octobre 2013- )

### C. ETUDES:

	Diplômes	Résultats	Dates	Lieu (Etablissement)
<i>HUMANITÉS :</i>				
Latin-Grec .....	.....	.....	Juin 1997...	Collège Sacré Cœur Charleroi.....
<i>UNIVERSITAIRES:</i>				
1ère Candidature .....	D.....	.....	Juin 1998...	Université catholique de Louvain (UCL) Woluwé
2ème Candidature .....	S.....	.....	Juin 1999...	U C L Woluwé .....
3ème Candidature .....	D.....	.....	Juin 2000...	U C L Woluwé .....
1er Doctorat .....	D.....	.....	Juin 2001...	U C L Woluwé .....
2ème Doctorat .....	GD.....	.....	Juin 2002...	U C L Woluwé .....
3ème Doctorat .....	GD.....	.....	Juin 2003...	U C L Woluwé .....
4ème Doctorat .....	GD.....	.....	Juin 2004...	U C L Woluwé .....
<i>SPECIALISATIONS:</i>				
Médecine interne .....	.....	.....	2008	UCL Woluwé .....
Oncologie .....	.....	.....	2013 ..	UCL Woluwé.....

### D. BOURSES OFFICIELLES:

	Dates	Lieu (Etablissement)
Télévie.....	.....	2009-2013 UCL Woluwé

### E. MEMOIRES DE « DES », THESE de DOCTORAT ou d'AGREGATION DE L'ENS.SUPERIEUR:

- Thèse de Doctorat en Sciences Pharmaceutiques: "Dealing with resistances to mTOR inhibitors in bladder and breast cancer" 2009-2013, UCL Woluwé. Promoteur: Prof Olivier Feron et Jean-Pascal Machiels. Défense le 17 novembre 2013.

- Certificat universitaire en science et médecine des animaux de laboratoire, (2010) UCL Woluwé

**F. EXPERIENCE PROFESSIONNELLE :**

Oncologue médical Hôpital de Jolimont	2013-
Chef de service adjoint oncologie médicale	2020-
Chargé de cours infirmière oncologie Haute Ecole Louvain en Hainaut	2013-
Coordinateur Concertation Multidisciplinaires Uro-oncologiques des cliniques Saint Luc	2021-
Coordinateur clinique du Sein Groupe Jolimont (Nivelles)	2016-2019

**G. NOMINATIONS ACADEMIQUES ET/OU CLINIQUES :**

*Date*

MD PhD .....	2013-
--------------	-------

**H RESPONSABILITES ACADEMIQUES ET/OU CLINIQUES :**

*Date*

Chef de service adjoint, département d'oncologie Hôpital de Jolimont .....	2020-2023
Coordinateur Concertation Multidisciplinaires Uro-oncologiques des cliniques Saint Luc	2021-
Chargé de cours infirmière oncologie Haute Ecole Louvain en Hainaut	2013-

**I. MEMBRES DE SOCIETES SCIENTIFIQUES :**

*Date*

American Society of Clinical Oncology (ASCO)	2013-
European Society of Medical Oncology (ESMO)	2013-
Belgian Society of Medical Oncology (BSMO)	2013-
Fonds de la recherche médicale en Hainaut (FRMH)	2016-
International Society for the Study of Vascular Anomalies (ISSVA)	2018-

**K. ACTIVITES SCIENTIFIQUES :\_ En annexe 1, suivre l'ordre des catégories ci-dessous; au sein de chaque catégorie, respecter l'ordre de date et les caractéristiques suivantes des références**

1. Articles (« full papers ») dans des revues avec comité de lecture :

- **Seront E**, de Saint-Hubert G, Gilbeau JP, Van Ruyseveldt P, Derue G. About two intra-aortic masses. Eur J Intern Med. 2008;19(6):e15-e17 (IF 2008 0.99)
- **Seront E**, Machiels JP. Targeted therapy in metastatic renal cell carcinoma. Journal of Belgian Society of Medical Oncology, January 2008.
- **Seront E**, Machiels JP. Targeted therapies in the treatment of advanced renal cell carcinoma. Recent Pat Anticancer Drug Discov. 2009;4(2):146-156. (IF 2009 3.044)
- **Seront E**, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. Cancer Treat Rev. 2010;36 Suppl 1:S11-S14. (IF 2010 7.63)
- **Seront E**, Baurain JF. Update in malignant Melanoma. Journal of Belgian Society of Medical Oncology, May 2010.
- **Seront E**, Machiels JP. New therapeutic perspective in renal cell carcinoma. Louvain Medical 2010
- **Seront E**, Mazzeo F, Mano M, et al. New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report. Acta Clin Belg. 2011;66(6):426-428. (Impact Factor 2010 0.66)
- **Seront E**, Van den Eynde M. Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases?. Clin Colorectal Cancer. 2012;11(3):177-184. (IF 2012 1.78)

- **Seront E**, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. *Ann Oncol.* 2012;23(10):2663-2670. (IF 2012 6.077)
- **Seront E**, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. *Br J Cancer.* 2013;109(6):1586-1592. (IF 2013 5.23)
- **Seront E**, Boidot R, Bouzin C, et al. Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours. *Br J Cancer.* 2013;109(10):2597-2606. (IF 2013 5.23)
- Draoui N, Schicke O, **Seront E**, et al. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. *Mol Cancer Ther.* 2014;13(6):1410-1418. (IF 2014 5.9)
- **Seront E**, Machiels JP. Molecular biology and targeted therapies for urothelial carcinoma. *Cancer Treat Rev.* 2015;41(4):341-353. (IF 2015 9.35)
- Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, Mendola A, Natynki M, **Seront E**, Dupont S, Hammer J, Legrand C, Brugnara C, Eklund L, Vikkula M, Bischoff J, Boon LM. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. *J Clin Invest.* 2015;125(9):3491-504. (IF 2015 11.69)
- van Marcke C, Ledoux B, Petit B, **Seront E**. Rapid and fatal acute heart failure induced by pazopanib. *BMJ Case Rep.* 2015;2015:bcr2015211522
- **Seront E**, Rottey S, Filleul B, et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. *BJU Int.* 2016;118(3):408-415. (IF 2016 4.33)
- Galot R, Christian N, Bitar M, **Seront E**. Unusual presentation of bladder cancer resurgence and efficacy of radiotherapy. *BMJ Case Rep.* 2016;2016:bcr2015213538.
- **Seront E**, Kidd F, Metz T, Van Ruyssevelt P. Atypical case of ecthyma gangrenosum mimicking a breast cancer recurrence. *BMJ Case Rep.* 2016;2016:bcr2016214349.
- **Seront E**, Limaye N, Boon LM, Vikkula M. Rapamycin opens the era of targeted molecular therapy of venous malformations. *Med Sci (Paris).* 2016 Jun-Jul;32(6-7):574-8.
- Machiels JP, Van Maanen A, Vandembulcke JM, Filleul B, **Seront E**, et al. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. *Oncologist.* 2016 Dec;21(12):1416-e17. (IF 2016 3.95)
- **Seront E**, Machiels JP. Immunotherapy for genito-urinary cancers: where are we ? *Belg J Med oncol Special edition* 2017; p 3-11
- van Marcke C, **Seront E**, Docquier C, Filleul B. Palmar fasciitis and polyarthritits, a rare paraneoplastic syndrome related to ovarian cancer. *Clin Exp Dermatol.* 2017;42(3):328-330. (IF 2017 0.59)
- **Seront E**, Vikkula M, Boon LM. Venous Malformations of the Head and Neck. *Otolaryngol Clin North Am.* 2018;51(1):173-184. (IF 2018 1.51)
- Hammer J, **Seront E**, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux C, Chopinet C, Clapuyt P, Hammer F, Vikkula M, Boon LM. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. *Orphanet J Rare Dis.* 2018 Oct 29;13(1):191 (IF 2018 3.687)
- **Seront E**, Catala G, Dermine A, Lejeune S, Rysselink S. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. *Future Sci OA.* 2018;4(10):FSO341. (IF 2018 1.81)
- **Seront E**, Van Damme A, Boon LM, Vikkula M. Rapamycin and treatment of venous malformations. *Curr Opin Hematol.* 2019;26(3):185-192. (IF 2019 3.09)
- **Seront E**, Schmitz S, Papier M, et al. Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. *Front Oncol.* 2019;9:155 (IF 2019 4.81)
- Dhenin A, Samartzi V, Lejeune S, **Seront E**. Cascade of immunologic adverse events related to pembrolizumab treatment. *BMJ Case Rep.* 2019;12(6):e229149
- Bossi P, **Seront E**, Machiels JP. May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer? *Oral Oncol.* 2019 Jul;94:121-122. (IF 2019 3.97)
- Pierrard J, Petit B, Lejeune S, **Seront E**. Isolated adrenocorticotrophic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab. *BMJ Case Rep.* 2019;12(8):e230848.

- Van den Bossche V, Jadot G, Grisay G, Pierrard J, Honoré N, Petit B, Augusto D, Sauvage S, Laes JF, **Seront E**. c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis. *Target Oncol*. 2020;15(1):139-146. (IF 2019 4.036)
- Pierrard J, **Seront E**. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review. *Curr Oncol*. 2019;26(6):395-403. (IF 2019 2.25)
- Ost P, Schrijvers D, Duck L, Gizzi M, Goffin K, Joniau S, Rottey S, Roumeguère T, Seront E, Withofs N, Tombal B. Appropriateness of treatment options in patients with mCRPC with a focus on Radium-223: outcomes of a Belgian multidisciplinary consensus meeting. *Belg J Med Oncol* 2019;13(6): 240–250 (IF 2019 not yet)
- Radermecker L, Rysselink S, **Seront E**. Laparoscopic partial cystectomy for venous malformation of the bladder. *Urol Case Rep*. 2020;32:101269.
- Dekeuleneer V, **Seront E**, Van Damme A, Boon LM, Vikkula M. Theranostic Advances in Vascular Malformations. *J Invest Dermatol*. 2020;140(4):756-763. (IF 2020 8.5)
- Van Damme A, **Seront E**, Dekeuleneer V, Boon LM, Vikkula M. New and Emerging Targeted Therapies for Vascular Malformations. *Am J Clin Dermatol*. 2020;21(5):657-668. (IF 2020 7.4)
- **Seront E**, Jamar F, Goffin K, Billiet I, Vanhaunderde V, Van den Eeckhaut A, Willems S, De Wil P, Sacré A, Mahy N, Bierlaire R, Deferme J, Schrijvers D. BELFIGO: a retrospective observational study to evaluate the treatment patterns of mCRPC patients in Belgium treated with Radium-223. *Belg J Med Oncol* 2020;14(7):347-54 (IF 2020 not yet)
- Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor. Hendrix A, Yeo AE, Lejeune S, **Seront E**. *BMJ Case Rep*. 2020;13(6):e235249.
- Grisay G, Percy C, Pierrard J and **Seront E**. A rare but life-threatening pneumopathy induced by Olaparib: From a clinical case to a review of literature *Journal of Translational Science* 2020, 6: DOI: 10.15761/JTS.1000366 (IF 2020 2.1)
- Grisay G, Pierrard J, Confente C, **Seront E**. Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. *Curr Treat Options Oncol*. 2020;22(1):7. (IF2020 4.6)
- Queisser A, **Seront E**, Boon LM, Vikkula M. Genetic Basis and Therapies for Vascular Anomalies. *Circ Res*. 2021;129(1):155-173. (IF 2021 23.2)
- Soutif C, Tison T, Focant I, **Seront E**. Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management. *Future Sci OA*. 2021;7(5):FSO706. (IF 2021 2.96)
- van Marcke C, Honoré N, van der Elst A, ... **Seront E**,... et al. Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study. *BMC Cancer*. 2021;21(1):578. (IF 2021 4.6)
- Louvet A, van Marcke C, D'Abadie P, **Seront E**. Successful treatment with yttrium-90 microspheres in a metastatic breast cancer patient and sclerosing cholangitis. *Future Sci OA*. 2021;7(7):FSO716. (IF 2021 2.92)
- Martinez Chanza N, Soukane L, Barthelemy P, ... **Seront E**, ... et al. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). *BMC Cancer*. 2021 Dec 2;21(1):1292.(IF 2021 4.63)
- Delchambre E, Rysselink S, Pairet G, Confente C, **Seront E**. Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature. *Future Sci OA*. 2021;7(6):FSO707. (IF 2021 2.92)
- Hirsch L, Martinez Chanza N, Farah S, ... **Seront E**... ,et al. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. *JAMA Oncol*. 2021 Dec 1;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. Erratum in: *JAMA Oncol*. 2021 1;7(12):1904. (IF 2021 33)
- Yeo AE, Hendrix A, Confente C, Christian N, Mansvelt B, Pairet G, **Seront E**. Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report. *Front Oncol*. 2021 Nov 17;11:764758. (IF 2021 6.24)
- **Seront E**, Lhommel R, Tombal B. Case Report: Early <sup>68</sup>Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases. *Front Oncol*. 2021;11:782166. (IF 2021 6.24)
- Houssiau H, **Seront E**. The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. *Cancers (Basel)*. 2022;14(7):1640. (IF 2021 6.5)
- Houssiau H, **Seront E**. Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. *Transl Oncol*. 2022;19:101387. (IF 2022 5)

- Houssiau H, Duhoux FP, François D, **Seront E**. Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report. *Front Oncol.* 2022;12:896301. (IF 202 4.42)
- Houssiau H, **Seront E**. Le rôle de l'immunothérapie dans le cancer urothélial. *Louvain médical* 2022, Vol. 141, no.3, p. 168-175
- **Seront E**, Dekeuleneer V, Coulie J, Van Damme A, Boon, LM, Vikkula M. Malformations vasculaires : un nouvel espoir grâce aux thérapies ciblées antitumorales. *Louvain médical* 2022, Vol 141, N°5, p 261-268.
- Geukens T, Brandão M, Laenen A, ... **Seront E... et al.**. Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future. *ESMO Open.* 2022 Dec;7(6):100610. (IF 2022 5.73)
- **Seront E**, Dekeuleneer V, van Damme A, Boon L, Vikkula M. Vascular malformations: repurposing the role of anti-cancer targeted molecular inhibitors. *Belg J Med Oncol* 2022;16(6):293–99 (IF 2022 not yet)
- Pierrard J, Tison T, Grisay G, **Seront E**. Global management of brain metastasis from renal cell carcinoma. *Crit Rev Oncol Hematol.* 2022 Mar;171:103600. (IF 2022 6.62)
- Santoni M, Myint ZW, Büttner T, ... **Seront E**, .. et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. *Cancer Immunol Immunother.* 2023 May 29. (IF 2023 6.63)
- Santoni M, Massari F, Myint ZW, ... **Seront E**, ... et al. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). *Clin Genitourin Cancer.* 2023 Mar 20:S1558-7673(23)00065-4. (IF 2023 3.2)
- Santoni M, Massari F, Myint ZW,... **Seront E** ...et al. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. *Target Oncol.* 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. (IF 2023 4.89)
- **Seront E**, Boon LM, Vikkula M. TEK-Related Venous Malformations. 2008 Sep 18 [updated 2023 Mar 2]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
- Verbiest A, Baldewijns M, Beuselinck B, Debruyne P, Gennigens C, Pelgrims G, Roumeguère T, **Seront E**, Sundahl N, Rottey S? Update on the management of renal cell carcinoma: The BSMO expert panel recommendations. *Belg J Med oncol* 2023; 17:118-27 (IF 2023 not yet)
- **Seront E**, Biard, J.M., Van Damme, A. et al. A case report of sirolimus use in early fetal management of lymphatic malformation. *Nat Cardiovasc Res* 2023 2, 595–599. (IF 2023 not yet)
- **Seront, E.**, Van Damme, A., Legrand, C., Bisdorff-Bresson, A., Orcel, P., Funck-Brentano, T., Sevestre, M. A., Dompmartin, A., Quere, I., Brouillard, P., Revencu, N., De Bortoli, M., Hammer, F., Clapuyt, P., Dumitriu, D., Vikkula, M., & Boon, L. M. (2023). Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. *JCI insight*, 8(21), e173095.
- **Seront E**, Froidure A, Revencu N, Dekeuleneer V, Clapuyt P, Dumitriu D, Vikkula M, Boon LM. Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus. *Orphanet J Rare Dis.* 2024 May 16;19(1):199.
- Zammit F, **Seront E**. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. *Pharmaceuticals (Basel).* 2024 Apr 14;17(4):501
- **Seront E**, Reichel C, Lhommel R, Tombal B. A Case Series Study of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Early Evaluation of the Response to Systemic Therapy in Metastatic Renal Cancer. *Eur Urol Oncol.* 2024
- Houssiau H, Pairet G, Dano H, **Seront E**. The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy. *Curr Oncol.* 2023

## 2. Chapitres de livres:

- **Seront E**, Machiels JP. Updates in Renal Cell carcinoma : new targeted therapies and new toxicities. Book Chapter, *Recent Patent Anticancer Drugs Discoveries* 2012.
- Parsyan A, **Seront E**, Machiels JP. Cancers of the urinary system. In: Armen Parsyan (ed.), *Translation and Its Regulation in Cancer Biology and Medicine*, Springer : Dordrecht 2014, p. 676-680

- **Seront E**, Machiels JP. Emerging targets and new agents in squamous cell carcinoma of the head and neck tumours. In: ESMO Head and Neck Essentials, 2017
- Boon LM, Vikkula M, **Seront E**. Venous malformations. In: Moise L. Levy, UpToDate, 2017

### 3. Proceedings publiés de congrès ou de conférences

### 4. Abstracts publiés de congrès ou de conférences

- **Seront E**, Yango J, Descamps O. Factor V and prothrombin polymorphisms in patients aged 75 years or older. Internal Medicine Congress Abstract, Brussels, november 2005 *Acta Clinica Belgica, Vol 60 2005. Poster presentation*
- **Seront E**, Rottey S, Filleul B, Goeminne JC, et al. Phase II trial of RAD001 monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy. American Society of Clinical Oncology 2010 (ASCO) Chicago, June 2010. *Poster presentation*
- **Seront E**, Rottey S, Boidot R, et al. Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers. American Society of Clinical Oncology (ASCO), Chicago June 2011. *Poster presentation*
- **Seront E**, Desaedeleer C, Boidot R, Feron O. Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell. Fifth European Organisation for Research and Treatment of Cancer (EORTC) annual meeting on Molecular Markers in Cancer, Brussels October 2011. *Poster presentation*
- **Seront E**, Boidot R, Feron O. Hypoxia decreases efficacy of mTOR inhibitors in MCF-7: role of autophagy. Belgian Association Cancer Research (BACR); Antwerpen, September 2013. *Poster presentation*
- **Seront E**, Rottey S, Filleul B, et al Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). American Society of Clinical Oncology (ASCO), Chicago, June 2015. *Poster presentation*
- Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, **Seront E**, et al Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy. American Society of Clinical Oncology (ASCO) Chicago, June 2015. *Poster presentation*
- **Seront E**, Schmitz S, Papier M, et al. Phase I study of RibocicliB plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). European Society of Medical Oncology congress (ESMO), Copenhagen, September 2016. *Poster presentation*
- van Marcke C, Petit B, Confente C, Filleul B, **Seront E**. Definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer: A retrospective analysis. ESMO European Cancer Congress, Vienna Septembre 2015. In: European Journal of Cancer, Vol. 51, no.S3, p. S575 (2015) *Poster presentation*
- van Marcke C, Petit B, Confente C, Filleul B, **Seront E**. Retrospective analysis of definitive chemoradiotherapy with either high-dose or weekly cisplatin in patients with locally advanced squamous cell head and neck cancer : 2-year outcome..ECCO Congress (Amsterdam January 2017). In: European Journal of Cancer, Vol. 72, no.S1, p. S106 (2017) *Poster presentation*
- Boon LM, Hammer J, **Seront E**, Dupont S, Hammer F, et al. Rapamycin as Novel Treatment for Refractory-to-Standard-Care Slow-Flow Vascular Malformations..Plastic Surgery 2015: Plastic Surgery The Meeting (Boston October 2015). In: Plastic and Reconstructive Surgery, Vol. 136, no.4 Suppl. p. 38 (2015) *Poster presentation*
- **Seront E**, Ledoux B, Confente C, Neybuch Y, Christian N. The docetaxel-abiraterone acetate sequence compared to the abiraterone acetate-docetaxel sequence in metastatic castration-resistant prostate cancer patients with a response to previous castration superior to 12 months. American Society of Clinical Oncology Genito-urinary symposium, San Francisco February 2018. *Poster presentation*

- **Seront E**, Confente E, Petit B et al. A guided and personalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue. European Society of Medical Oncology congress (ESMO) Munich, October 2018. *Poster presentation*
- Van DenBossche V, Jadot G, **Seront E**. c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis. Belgian society of Medical Oncology, Brussels February 2020. *Poster presentation*
- Honoré N, **Seront E**. The role of metformin in treatment of breast cancer. Belgian Society of Medical Oncology (BSMO), Brussels, February 2020. *Poster presentation*
- **Seront E**, Bisdorff Bresson A, Domp martin A, Boon LM, Vikkula M. VASE trial evaluating Sirolimus in Vascular Malformations refractory to Standard Care: Beyond the 2-year treatment with sirolimus. Vascular Anomalies Congress (VAC), Brussels, February 2023 *Poster presentation*.
- Coulie J, **Seront E**, Boon LM, Vikkula M. TRAMAV trial: evaluation of trametinib in arteriovenous malformation. Vascular Anomalies Congress (VAC), Brussels, February 2023. *Poster presentation*
- Hasssayoune N, Coulie J, **Seront E**, Boon LM, Vikkula M Sirolimus: friend or enemy of surgeons dealing with vascular anomalies? Vascular Anomalies Congress (VAC), Brussels, February 2023. *Poster presentation*

5. Présentations publiques ou sur invitation (titre, auteurs, nom de la société où le travail a été présenté, la ville, le mois et l'année de la présentation)

- **Seront E**, Rottey S, Filleul B, et al. Phase II trial of Everolimus monotherapy in the palliative treatment of patients with metastatic Transitional Cell Carcinoma after failure of platinum-based therapy: activity and biomarkers. Belgian society of Medical Oncology (BSMO), Brussels February 2011.
- **Seront E**, Boidot R, Machiels JP, Feron O. Translational research; analysis of RAD001 efficacy in patients with metastatic transitional cell carcinoma. Fond National de la Recherche Scientifique (FNRS) - Télévie, Liège, September 2012
- **Seront E** and Tombal B. About translational research in metastatic bladder cancer. European Urology Tour organized by Cliniques Universitaires Saint Luc, Brussels, June 2012.
- **Seront E**, Boidot R, Pinto A et al. Role of autophagy in cancer cells resistance to mTOR inhibitors. Fond National de la Recherche Scientifique (FNRS) – Télévie, Brussels, June 2012.
- **Seront E**, Boidot R, Feron O. Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors. Belgian Association of Cancer Research (BACR), Antwerp September 2013.
- **Seront E**, Boidot R, Feron O, Machiels JP. Role of Akt activation induced by mTOR inhibitors in development of resistance to mTOR inhibitors. Belgian Society of Medical Oncology (BSMO), Brussels February 2013.
- **Seront E**. The role of neoadjuvant chemotherapy in head and neck cancer. Belgian Multidisciplinary symposium. Head and Neck symposium, La Hulpe June 2014.
- **Seront E**. The sequence of systemic therapies in advanced head and neck cancer. Belgian Multidisciplinary symposium Head and Neck symposium, La Hulpe, May 2015.
- **Seront E** and Tombal B. Preceptorship Program on Prostate Cancer June 2015, Brussels
- **Seront E**. Highlights of ASCO GU. Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) La Hulpe, March 2016.
- **Seront E**. Targeted therapies in head and neck cancer; Belgian Multidisciplinary symposium Head and Neck symposium La Hulpe May 2016.
- **Seront E**. Immune checkpoint inhibitors in head and neck cancer. Multidisciplinary symposium Head and Neck symposium La Hulpe, May 2017.
- **Seront E**. Immunotherapy in bladder cancer. Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC), La Hulpe, March 2017
- **Seront E**. Immunotherapy in bladder cancer. Oral presentation Belgian Society of Medical Oncology (BSMO), Ostende, February 2018
- **Seront E**. Highlights of ASCO GU. Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) La Hulpe, March 2018.
- **Seront E**. Targeted therapies in advanced renal cancer. Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 2019; La Hulpe, December 2018
- **Seront E**, Bisdorff Bresson A, Domp martin A, Boon LM, Vikkula M. A phase III trial evaluating sirolimus in vascular Malformations. International Society for the Study of Vascular Anomalies (ISSVA) Amsterdam, May 2018.



- **Seront E.** Highlights in head and neck cancer. Belgian Multidisciplinary symposium Head and Neck symposium La Hulpe, January 2019.
- **Seront E.** Post ESMO: Highlights, Belgian Society of Medical Oncology (BSMO). Namur Octobre 2018
- **Seront E.** Highlights of ASCO GU. Oral presentation Belgian Multidisciplinary Urological Cancer (BMUC) La Hulpe, March 2019
- **Seront E.** Targeted therapies in head and neck cancer. Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 2019; La Hulpe, December 2019
- **Seront E, Bisdorff Bresson A, Domp martin A, Boon LM, Vikkula M.** Molecular Therapies for Vascular Malformations: Rapamycin and Beyond International Society for the Study of Vascular Anomalies (ISSVA) May 2020 online
- **Seront E.** Systemic treatment in bladder cancer: focus on elderly. Journée d'Onco-Urologie Médicale (JOUM), Avignon, May 2019.
- **Seront E.** Post ESMO: Highlights, Belgian Society of Medical Oncology (BSMO). Namur Octobre 2019
- **Seront E.** Place of PARP inhibitor in prostate cancer. Journée d'Onco-Urologie Médicale (JOUM), Paris, May 2020.
- **Seront E.** Post ESMO: Highlights, Belgian Society of Medical Oncology (BSMO). Namur Octobre 2020
- **Seront E.** Targeted therapies in head and neck cancer. Belgian Multidisciplinary symposium Head and Neck symposium, La Hulpe, January 2020.
- **Seront E.** Post ESMO: Highlights, Belgian Society of Medical Oncology (BSMO). Namur Octobre 2021
- **Seront E.** Systemic therapies in advanced renal cancer. Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 2020; La Hulpe, December 2022.
- **Seront E, Van Damme A, Boon L, Vikkula M.** In utero treatment of vascular malformation with sirolimus. International Society for the Study of Vascular Anomalies (ISSVA), Melbourne, May 2021.
- **Seront E.** 10ème Journée oncologique de Chimay. Immunothérapie et toxicité ; Chimay, Juin 2021
- **Seront E, Van Damme A, Boon L, Vikkula M.** Evaluation of PIK3CA mutated patients with vascular malformation in the VASE trial. PIK3CA meeting June 2021, Boston
- **Seront E, Bisdorff Bresson A, Domp martin A, Boon LM, Vikkula M.** Preliminary results of the VASE trial evaluating Sirolimus in Vascular Malformations refractory to Standard Care: Beyond the 2-year treatment with sirolimus. International Society for the Study of Vascular Anomalies (ISSVA) May 2022 Vancouver
- **Seront E.** Post ESMO: Highlights, Belgian Society of Medical Oncology (BSMO). Namur Octobre 2022
- **Seront E.** Targeted therapy in prostate cancer. Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 2022; La Hulpe, December 2022.
- **Seront E, Bisdorff Bresson A, Domp martin A, Boon LM, Vikkula M.** VASE trial evaluating Sirolimus in Vascular Malformations refractory to Standard Care: Beyond the 2-year treatment with sirolimus. Vascular Anomalies Congress (VAC 2023), Brussels, February 2023
- **Seront E, Froidure A, Boon LM, Vikkula M.** Association of sirolimus and trametinib in complex lymphatic anomaly. International Society for the Study of Vascular Anomalies (ISSVA) May 2023, Boston.
- **Seront E, Vuylsteke C, Tombal B.** Roundtable Post-ASCO: highlights. Zaventem, July 2023

**L. RESPONSABILITES ET ACTIVITES SCIENTIFIQUES** depuis la dernière promotion :  
à joindre en annexe 2